

# CITATION REPORT

List of articles citing

**Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide**

**DOI: 10.1160/th15-05-0415**

**Thrombosis and Haemostasis, 2016, 115, 368-81.**

**Source:** <https://exaly.com/paper-pdf/63322652/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
57	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. <i>Vascular Health and Risk Management</i> , <b>2016</b> , 12, 45-51	4.4	4
56	Edoxab�. Propiedades farmacocin�icas y farmacodin�icas. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2016</b> , 16, 60-66	0.2	2
55	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , <b>2016</b> , 20, 273	10.8	16
54	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. <i>TrAC - Trends in Analytical Chemistry</i> , <b>2016</b> , 84, 41-50	14.6	12
53	The Taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban. <i>International Journal of Laboratory Hematology</i> , <b>2017</b> , 39, e60-e63	2.5	11
52	Laboratory Assessment of Direct Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 277-290	5.3	60
51	Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. <i>Thrombosis Research</i> , <b>2017</b> , 156, 36-38	8.2	16
50	Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay. <i>Thrombosis Research</i> , <b>2017</b> , 155, 121-127	8.2	16
49	Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2017</b> , 55, 1349-1359	5.9	23
48	Direct oral anticoagulant reversal: how, when and issues faced. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 1005-1022	2.8	2
47	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , <b>2017</b> , 6, 91-117	1.4	3
46	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , <b>2017</b> , 31, 77-84	11.1	116
45	Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS). <i>Hamostaseologie</i> , <b>2017</b> , 37,	1.9	5
44	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. <i>Vascular Health and Risk Management</i> , <b>2017</b> , 13, 457-467	4.4	33
43	Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 251-265	5.1	23
42	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 437-450	7	159
41	Platelet aggregation impacts thrombin generation assessed by calibrated automated thrombography. <i>Platelets</i> , <b>2018</b> , 29, 156-161	3.6	9

40	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 209-219	15.4	177
39	European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding. <i>European Journal of Anaesthesiology</i> , <b>2018</b> , 35, 96-107	2.3	7
38	Gastrointestinal bleeding in a patient on multiple medications including edoxaban. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , <b>2018</b> , 79, 650-651	0.8	
37	Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2018</b> , 78, 575-583	2	9
36	Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS). <i>Phlebologie</i> , <b>2018</b> , 47, 215-221	0.3	
35	Evaluation of the DOAC-Stop Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. <i>TH Open</i> , <b>2018</b> , 2, e202-e209	2.7	45
34	Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1203-1214	7	16
33	Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. <i>Thrombosis Research</i> , <b>2019</b> , 175, 61-67	8.2	6
32	Protein C Deficiency. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2019</b> , 143, 1281-1285	5	21
31	Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7). <i>Heart and Vessels</i> , <b>2019</b> , 34, 2011-2020	2.1	4
30	Patients on NOACs in the Emergency Room. <i>Current Neurology and Neuroscience Reports</i> , <b>2019</b> , 19, 40	6.6	2
29	Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1273-1287	15.4	32
28	Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4540-4553	3.3	13
27	In vitro assessment of edoxaban anticoagulant effect in pediatric plasma. <i>Thrombosis Research</i> , <b>2019</b> , 178, 112-118	8.2	2
26	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. <i>International Journal of Laboratory Hematology</i> , <b>2019</b> , 41, 250-261	2.5	7
25	Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7). <i>Heart and Vessels</i> , <b>2020</b> , 35, 409-416	2.1	5
24	Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 251-258	5.1	9
23	Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 35, 151-159	2.2	8

22	Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?. <i>Hamostaseologie</i> , <b>2020</b> , 40, 364-378	1.9	3
21	Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). <i>Current Pharmacology Reports</i> , <b>2020</b> , 6, 241-259	5.5	4
20	Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. <i>International Journal of Laboratory Hematology</i> , <b>2020</b> , 42, 636-642	2.5	12
19	Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 395-403	5.1	4
18	Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1866-1873	15.4	9
17	Reference values for thrombin dynamics in platelet rich plasma. <i>Platelets</i> , <b>2021</b> , 32, 251-258	3.6	1
16	Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43, 7-20	2.5	8
15	Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2021</b> ,	4	1
14	Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12523	5.1	
13	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , <b>2018</b> , 16, 462-470	3.6	35
12	Risk management of direct oral anticoagulant administration: An approach from the clinical laboratory. <i>Tenri Medical Bulletin</i> , <b>2016</b> , 19, 81-89	0	
11	The effects of direct oral anticoagulants on congenital thrombophilia. <i>Japanese Journal of Thrombosis and Hemostasis</i> , <b>2018</b> , 29, 20-27	0	
10	Consenso sulla diagnostica di laboratorio per i pazienti in trattamento con farmaci anticoagulanti ad azione diretta. Sottoscritto dalla Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET), dalla Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), dalla Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica	1.1	
9	Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 1-12 <i>Clinica Di Laboratorio</i> , <b>2019</b> , 15,	6.3	2
8	Recommendations from the ICM-VTE: General.. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2022</b> , 104, 4-162	5.6	0
7	The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12680	5.1	1
6	The Myths Behind DOAC Measurement: Analyses of Prescribing Information from Different Regulatory Bodies and a Call for Harmonization.		0
5	Direct oral anticoagulants (DOACs): From the laboratory point of view. <b>2022</b> , 72, 459-482		0

- 4 Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls. **2022**, 6, ☐
- 3 How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?. ☐
- 2 DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. **2023**, 21, 433-452 ☐
- 1 Direct Oral Anticoagulants: Laboratory Challenges and Antidotes. **2023**, 43, 037-043 ☐